BMO Capital Reiterates Outperform Rating on Ascendis Pharma (ASND)

September 10, 2026 2:56 AM

BMO Capital analyst David Lebowitz reiterated an Outperform rating and $319.00 price target on Ascendis Pharma (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found